Inflammatory Bowel Disease Models Research using animal models of IBD (both Crohn's-like and ulcerative colitis-like conditions) has shown BPC-157 [12]: Reduces intestinal inflammation Accelerates mucosal healing Preserves intestinal barrier function Decreases inflammatory cytokine production Prevents fistula formation in some models Intestinal Anastomosis Healing Surgical studies demonstrated that BPC-157 significantly improves the healing of intestinal anastomoses (surgical connections), potentially reducing complications like leakage and stricture formation [13]
Manufactured under strict quality standards to ensure reliable performance
Our explainer on how tirzepatide influences incretin pathways and the overview at what tirzepatide (Mounjaro/Zepbound) is and how it works walk through the receptor pharmacology
BPC-157 Standalone Targeted tissue repair and inflammation support A synthetic peptide derived from a naturally occurring protein, BPC-157 promotes angiogenesis, improves blood flow to damaged areas, and supports healing across musculoskeletal and gastrointestinal systems at the cellular level
GLOW Peptide Regulatory Status As of June 2026, none of the three GLOW compounds (BPC-157, TB-500, GHK-Cu) are FDA-approved for injectable human use
Biochemistry 50 , 82218225 (2011)
